In connection with the company’s decision to develop a nasal vaccine candidate for influenza, based on recent progress with its mucosal vaccine platform, the board of Abera has decided to
Biotech
The two biologics Contract Development and Manufacturing Organizations (CDMOs), have announced their combination. Backed by their common shareholder, Keensight Capital, the combination of Biovian and 3P extends the group’s value
The company has decided to discontinue the preclinical development of the lipodystrophy project CGT2. After receiving data that was difficult to interpret during the course of the project, CombiGene conducted
In October 2023, Nykode completed a private placement round of approx NOK 505 million and this week, the company revealed that CapitalGroup, one of the world’s ten largest capital management
Norwegian biotech company Arxx Therapeutics will merge with Dutch pharma company Oxitope Pharma to create Calluna Pharma Inc. The merger followed a completed Series A round of EUR 75 million,
The Board of Directors of Xbrane Biopharma has announced a rights issue of units of approximately SEK 343 million, consisting of shares and warrants of series TO1. Upon full exercise
The board of directors of Medivir has resolved on a directed issue through which the company receives approximately SEK 20 million before issue costs. The right to subscribe for shares
FluoGuide plans to expand the scope of application of FG001 and advance its development toward approval in aggressive brain cancer. FluoGuide has obtained clinical proof of concept of FG001, a
The manufacturing license paves the way for Anocca’s near-term path to the clinic and long-term strategy to advance franchises of precision targeted cell therapies for different cancers and covering diverse